Bluejay Therapeutics, a developer of therapeutics for functional cures of chronic hepatitis B virus (HBV) infection, and Lonza, a global CDMO, entered a manufacturing agreement for BJT-778, one of Bluejay’s lead candidates. This monoclonal antibody (mAb), targeting the HBV surface antigen (HBsAg), is currently under preclinical development for the restoration of patient’s adaptive immunity and functional cure for chronic HBV infection. Under the terms of the agreement, Lonza has tailored its Ibex® Design offering to manufacture cGMP material for BJY-788 for pre-clinical and clinical testing. Source: Genetic Engineering News 18/11/2021